Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Administered as a once-weekly subcutaneous injection, Ozempic not only helps control blood glucose levels but also reduces ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

Close to 2.3 million seniors in Medicare are using the semaglutide medications, branded as Ozempic, Rybelsus and Wegovy by Novo Nordisk. Medicare says that the drug added up to more than $14 ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Medicare spent $14.4 billion on Ozempic and Wegovy, as well as their sister medication Rybelsus, between November 2023 and October 2024. The medications, manufactured by Novo Nordisk and used to ...

Popular diabetes and weight-loss drugs Ozempic, Rybelsus and Wegovy are among 15 drugs selected by the Biden administration for a second annual round of Medicare price negotiations meant to bring ...

In addition to Ozempic and Wegovy, other prescription medications selected for negotiations include Calquence, Trelegy Ellipta, Rybelsus, Linzess and Otezla. "These selected drugs accounted for ...

Wegovy has been approved by the Food and Drug Administration (FDA) for weight loss. Ozempic has been approved for diabetes, though it's sometimes still used for weight loss. Rybelsus is a similar drug ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027. The ...